Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV003133394 | SCV000714582 | uncertain significance | not provided | 2024-12-06 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000690819 | SCV000818547 | likely benign | Nemaline myopathy 2 | 2025-01-10 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003133394 | SCV003812818 | uncertain significance | not provided | 2023-01-13 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000690819 | SCV001454440 | uncertain significance | Nemaline myopathy 2 | 2019-12-30 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004737885 | SCV005359492 | uncertain significance | NEB-related disorder | 2024-03-31 | no assertion criteria provided | clinical testing | The NEB c.24146T>C variant is predicted to result in the amino acid substitution p.Val8049Ala. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.040% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |